KORU Medical Systems, Inc. (NASDAQ: KRMD), a prominent medical technology company specializing in the development, manufacturing, and commercialization of large volume subcutaneous infusion solutions, has recently announced a collaboration aimed at launching a feasibility study. The study will investigate the use of KORU’s Freedom Infusion System, in partnership with a leading global pharmaceutical manufacturer, for the administration of a rare disease therapy that is already commercially available.
The collaboration, initiated by KORU Medical, marks a significant step for the company in penetrating the ambulatory infusion market. The Freedom Infusion System, known for its patient-centric approach, is designed to enable the delivery of large volume subcutaneous infusions. The feasibility study will assess the system’s compatibility and effectiveness with the existing rare disease therapy.
KORU Medical’s commitment to innovation and patient care is reflected in its focus on developing advanced infusion solutions. By entering the ambulatory infusion settings with the commercialized biologic therapy, the company aims to expand its reach and contribute to improving patient experiences. The collaboration with the global pharmaceutical manufacturer will allow KORU Medical to leverage its expertise and resources to conduct a comprehensive analysis of the feasibility of their infusion system in this specific therapy context.
This move by KORU Medical Systems showcases their dedication to advancing medical technology and addressing unmet needs in the healthcare industry. By targeting the market of ambulatory infusion settings, the company demonstrates a commitment to providing effective and patient-centric solutions for rare disease therapy administration.
The initiation of the feasibility study highlights KORU Medical’s proactive approach to collaborating with industry leaders, leveraging cutting-edge technologies, and exploring new avenues for growth. The outcome of the study is poised to provide valuable insights into the potential commercialization of the Freedom Infusion System in the ever-evolving ambulatory infusion market.
In conclusion, KORU Medical Systems has announced a collaboration with a global pharmaceutical manufacturer to enter the ambulatory infusion market with a feasibility study focused on a commercialized rare disease therapy. This endeavor signifies the company’s commitment to patient-centric innovation and represents an opportunity for KORU Medical to expand its reach within the healthcare industry. As the study progresses, the industry eagerly awaits the results to determine the potential impact of KORU’s advanced infusion system in the ambulatory infusion setting.
Comments